Meridiano

Add Article

No Image Available

Article Details

Title

Article: GeneHarbor plans Hong Kong IPO to fund new medicinal products, widen anti-ageing supplements line

Impact Score

5 / 10

AI Summary (Processed Content)

GeneHarbor, a Hong Kong-based producer of anti-ageing supplements, plans an IPO before June next year to raise capital. The funds will be used to diversify from supplements into developing medicinal compounds, particularly for treating neurological diseases like Alzheimer's.

The company recently invested heavily in a new production facility in Zhejiang province to manufacture NMN, a compound it claims has anti-ageing and potential Alzheimer's treatment properties. This listing would be notable as Hong Kong's market has been dominated by mainland biotech firms since regulatory changes in 2018.

The main topics covered are GeneHarbor's IPO plans, its business diversification from supplements to medicines, and the expansion of its NMN production capacity.

Original URL

https://www.scmp.com/business/companies/article/3102651/geneharbor-plans-hong-kong-ipo-fund-new-medicinal-products-widen?utm_source=rss_feed

Source Feed

Science & Research - South China Morning Post

Published Date

2020-09-23 06:05

Fetched Date

2026-03-04 14:32

Processed Date

2026-03-04 15:12

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

Advertisement
GeneHarbor plans Hong Kong IPO to fund new medicinal products, widen anti-ageing supplements line
- GeneHarbor, which produces anti-ageing supplements, wants to diversify into medicines, CEO Wang Jun says
- Firm added new production line this year in Zhejiang province to produce NMN, which has potential to treat Alzheimer’s
3-MIN READ3-MIN
A home-grown Hong Kong company plans to join a growing list of firms tapping the city’s stock market for capital for health care-related investment amid the Covid-19 pandemic.
GeneHarbor (Hong Kong) Biotechnologies, which produces anti-ageing supplements, plans to make an initial public offering before June next year for funds to develop compounds to treat neurological diseases such as Alzheimer’s, chief executive officer Wang Jun said.
“We are [already] a profitable company,” he told the Post in an interview. “The reason we want to raise money is to extend our product line and diversify from supplements into medicines.”
Advertisement
The dietary supplement producer, established in 2004, spent 2 billion yuan (US$294 million) to build a factory this year in Ningbo in eastern Zhejiang province, capable of producing 100 tonnes of nicotinamide mononucleotide (NMN) annually. The company claims the compound helps delay the ageing process and has the potential to treat Alzheimer’s.
Advertisement
A successful listing would be a rare feat for Hong Kong, which has hosted predominantly mainland China-based biotechnology firms since an April 2018 reform opened the floodgate for so-called pre-profit drugs and medical device developers to sell shares to the public.
Advertisement
Select Voice
Select Speed
1.00x